Switching to DTG/3TC is non-inferior to continuing current antiretroviral regimen at week 48: SALSA subgroup analyses

被引：0
|
作者：
Taylor, S. [1 ]
Andrade-Villanueva, J. F. [2 ]
Kaplan, R. [3 ]
Nahass, R. [4 ]
Hocqueloux, L. [5 ]
Scholten, S. [6 ]
Di Giambenedetto, S. [7 ,8 ]
Galera, C. [9 ]
Blair, L. [10 ]
Wynne, B. [10 ]
Oyee, J. [11 ]
Underwood, M. [10 ]
Curtis, L.
Bontempo, G. [10 ]
van Wyk, J. [12 ]
机构：
[1] Birmingham Heartlands Hosp, Birmingham, W Midlands, England
[2] Hosp Civil Fray Antonio Alcalde, Guadalajara, Mexico
[3] Desmond Tutu Hlth Fdn, Cape Town, South Africa
[4] IDCare, Hillsborough, North Ireland
[5] Ctr Hosp Reg Orleans, Orleans, France
[6] Praxis Hohenstaufenring, Cologne, Germany
[7] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli IRCC, UOC Malattie Infett, Rome, Italy
[8] Univ Cattolica Sacro Cuore, Dipartimento Sicurezza & Bioet, Sez Malattie Infett, Rome, Italy
[9] Hosp Clinico Univ Virgen Arrixaca, Murcia, Spain
[10] ViiV Healthcare, Res Triangle Pk, NC USA
[11] GlaxoSmithKline, Uxbridge, Middx, England
[12] ViiV Healthcare, Brentford, England
来源：
HIV MEDICINE | 2021年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
PE2/72
引用
收藏
页码：129 / 129
页数：1
相关论文
共 47 条
  • [21] Once-daily dolutegravir (DTG; S/GSK1349572) is non-inferior to raltegravir (RAL) in antiretroviral-naive adults: 48 week results from SPRING-2 (ING113086)
    Raffi, F.
    Rachlis, A.
    Stellbrink, H-J.
    Hardy, W. D.
    Torti, C.
    Orkin, C.
    Bloch, M.
    Podzamczer, D.
    Pokrovsky, V.
    Almond, S.
    Margolis, D.
    Min, S.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 55 - 55
  • [22] Efficacy and Safety of Switching to Dolutegravir/Lamivudine (DTG/3TC) in Treatment-Experienced, Virologically Suppressed PLHIV Aged ≥50 Years: Pooled Results From the TANGO and SALSA Studies
    Walmsley, S.
    Smith, D. E.
    Gorgolas, M.
    Cahn, P. E.
    Lutz, T.
    Lacombe, K.
    Kumar, P. N.
    Wynne, B.
    Grove, R.
    Bontempo, G.
    Moodley, R.
    Spinelli, F.
    Jones, B.
    Okoli, C.
    Ait-Khaled, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 123 - 124
  • [23] Improved metabolic parameters after switching from TAF-based 3-or 4-drug regimen to the 2-drug regimen of DTG/3TC (dolutegravir/lamivudine): The TANGO study
    van Wyk, J.
    Ait-Khaled, M.
    Santos, J.
    Scholten, S.
    Wohlfeiler, M.
    Ajana, F.
    Jones, B.
    Nascimento, M. C.
    Tenorio, A.
    Smith, D.
    Wright, J.
    Wynne, B.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 27 - 27
  • [24] Incidence of non-alcoholic fatty liver disease in antiretroviral therapy-naïve people with human immunodeficiency virus who start DTG/ABC/3TC compared to BIC/FTC/TAF at 48-week follow-up
    Diaz, Ana Luz Cano
    Gonzalez, Salma Triana
    Velazquez, Gloria Elizabeth Salinas
    Marin, Jose Antonio Mata
    Martinez, Jesus Enrique Gaytan
    Mauss, Stefan
    INTERNATIONAL JOURNAL OF STD & AIDS, 2025, 36 (01) : 36 - 41
  • [25] A Phase 3 randomized controlled clinical trial of bictegravir in a fixed dose combination, B/F/TAF, vs ABC/DTG/3TC in treatment-naive adults at Week 48
    Gallant, J.
    Lazzarin, A.
    Mills, A.
    Orkin, C.
    Podzamczer, D.
    Tebas, P.
    Girard, P-M
    Brar, I.
    Daar, E.
    Wohl, D.
    Rockstroh, J.
    Wei, X.
    White, K.
    Martin, H.
    Quirk, E.
    Cheng, A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 103 - 104
  • [26] Limb fat changes 48 weeks after switching from AZT/3TC to FTC/TDF versus continuing on AZT/3TC. Primary endpoint analysis of the RECOMB trial
    Martinez, E.
    Ribera, E.
    Clotet, B.
    Estrada, V.
    Sanz, J.
    Berenguer, J.
    Rubio, R.
    Pulido, F.
    Larrouse, M.
    Curran, A.
    Negredo, E.
    Arterburn, S.
    Ferrer, P.
    Alvarez, M. L.
    ANTIVIRAL THERAPY, 2008, 13 (08) : A47 - A48
  • [27] 48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial
    Y Yazdanpanah
    M-A Khuong-Josses
    L Hocqueloux
    G Pialoux
    J Durant
    B Wynne
    C Granier
    P Tebas
    K Pappa
    S Min
    BMC Infectious Diseases, 14 (Suppl 2)
  • [28] Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naive adults with HIV-1 infection-96-week results from the GEMINI studies
    Cahn, P.
    Sierra-Madero, J.
    Arribas, J.
    Antinori, A.
    Ortiz, R.
    Clarke, A.
    Hung, C. -C.
    Rockstroh, J.
    Girard, P. -M.
    Sievers, J.
    Man, C.
    Urbaityte, R.
    Underwood, M.
    Tenorio, A. -R.
    Pappa, K.
    Wynne, B.
    Gartland, M.
    Aboud, M.
    van Wyk, J.
    Smith, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 103 - 103
  • [29] SOLAR 3D: a prospective comparative study switching from 3-or 4-drug ART to DTG/3TC for maintenance of viral suppression in the setting of current and historical M184V/I and prior virologic failures: 48 week primary endpoint results
    Blick, G.
    Cerreta, E.
    Mancini, G.
    Cosenza, A.
    HIV MEDICINE, 2021, 22 : 122 - 123
  • [30] Incidence of non-alcoholic fatty liver disease in antiretroviral therapy-naive people living with HIV who start a regimen with DTG/ABC/3TC compared to those who start BIC/FTC/TAF at 48-week follow-up at the Hospital de Infectologia CMN 'La Raza': A preliminary analysis
    Cano-Diaz, A.
    Perez-Barragan, E.
    Triana-Gonzalez, S.
    Salinas-Velazquez, G. E.
    Rodriguez-Evaristo, M. S.
    Mata-Marin, J. A.
    Gaytan-Martinez, J. E.
    HIV MEDICINE, 2023, 24 : 181 - 182
12345